Study aims to predict outcomes in small blood vessel brain disease
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial is looking at how brain “small blood vessel disease” changes over time and what outcomes to expect. If you have certain symptoms or scan findings from this condition, your care team may compare your prognosis to help guide future treatment planning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of small blood vessel disease in the brain, such as hypertensive deep perforator arteriolopathy, cerebral amyloid angiopathy, or another genetic/sporadic small vessel disease (like CADASIL).
- Your condition must be clinically symptomatic (for example: brain bleed, stroke, memory/thinking problems) or show more severe findings on brain scans.
- If you have cerebral amyloid angiopathy, you may qualify if you meet recognized criteria and have symptoms such as brain bleeding, “amyloid spells,” cognitive impairment, or a higher burden of certain scan findings.
- If you have hypertensive deep perforator disease, you may qualify if you have symptoms (including brain bleed or stroke) or more severe scan findings.
- You should have an expected lifespan of at least 6 months from causes other than the small vessel disease, and you can realistically attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at people who may have “small vessel” problems in the brain, which can cause stroke, memory trouble, walking changes, movement symptoms, or headaches. It may help researchers better understand the genetic and non-genetic causes, which could improve future diagnosis and treatment.
This study looks at brain MRI scans in people with cerebral amyloid angiopathy (a condition where amyloid builds up in brain blood vessels). The goal is to search for “biomarkers,” or measurable scan features, to better understand and detect the disease in some people before symptoms or during symptoms.
This study collects blood and other biological samples from people with rare diseases affecting the brain's small blood vessels, such as CADASIL, and from healthy volunteers. The samples are used to better understand these diseases and improve future diagnosis and treatment.
This Phase 2 study tests AMDX-2011P to see if it can help people with cerebral amyloid angiopathy (CAA), a condition where abnormal protein affects blood vessels in the brain. You may be able to join if you have confirmed or likely CAA and a recent brain MRI showing changes from CAA.
This study follows people with cerebral small vessel disease (a condition where the small blood vessels in the brain are damaged) over time to learn more about how it progresses and how it affects people. Participating involves regular check-ins and MRI scans to monitor your health.
This study tracks people ages 30 to 60 who have signs of small vessel disease on brain MRI. It aims to understand the risk of dementia over the next 10 years, so you can get early monitoring and care.
Hear when a new Cerebral Amyloid Angiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.